Exploring Corresponding Cutpoints for Hypoglycaemia Awareness Questionnaire ( HypoA ‐Q) Impaired Awareness Subscale in Relation to the Gold and Clarke Measures: A Post Hoc Analysis From the Hypo‐ METRICS Study
ABSTRACT Aims The Hypoglycaemia Awareness Questionnaire–Impaired Awareness subscale (HypoA‐Q/IA) was developed to enhance impaired awareness of hypoglycaemia (IAH) assessment, addressing methodological deficiencies of the established Gold and Clarke measures. An IAH cutpoint (HypoA‐Q/IA ≥ 12) was identified from a clamp study in Type 1 diabetes (T1D). We explored cutpoints in relation to Gold and Clarke measures, and their co‐occurrence, in the larger, real‐world observational Hypo‐METRICS study, in people with T1D (pwT1D) and insulin‐treated Type 2 diabetes (pwT2D). Material and Methods Hypo‐METRICS recruited pwT1D or pwT2D with ≥ 1 hypoglycaemic event in the previous 3 months. IAH was defined as Gold ≥ 4, Clarke ≥ 4 and/or HypoA‐Q/IA ≥ 12. Bidirectional ROC analysis was performed between HypoA‐Q/IA and Gold/Clarke cutpoints. Results Questionnaires were completed by 232 pwT1D and 285 pwT2D (male 47% vs. 62%, p < 0.001; median age 49 vs. 63 years, p < 0.001; HbA1c 7.3% vs. 7.4%, p = 0.03). IAH prevalence was 24% by Gold ≥ 4, 16% by Clarke ≥ 4 and 7% by HypoA‐Q/IA ≥ 12. ROC analysis yielded HypoA‐Q/IA cutpoints of ≥ 7 against Gold ≥ 4 (AUC 0.87) and ≥ 9 against Clarke ≥ 4 (AUC 0.89), and cutpoints of Gold ≥ 4 (AUC 0.87) and Clarke ≥ 3 (AUC 0.93) against HypoA‐Q/IA ≥ 12. Of those with IAH by either measure, 24% were identified by both HypoA‐Q/IA ≥ 12 and Gold ≥ 4, and 32% by both HypoA‐Q/IA ≥ 12 and Clarke ≥ 4, with lower overlap in T2D than T1D. Conclusions HypoA‐Q/IA cutpoints corresponding to legacy IAH cutpoints (≥ 7–9) were lower than the clamp‐derived threshold (≥ 12), suggesting ≥ 12 may identify a subgroup with more severe IAH. These cutpoints enable cross‐study comparison; prospective validation against severe hypoglycaemia risk is needed.
Authors
- Stephanie A. Amiel (ORCID: https://orcid.org/0000-0003-2686-5531)
- Jane Speight (ORCID: https://orcid.org/0000-0002-1204-6896)
- Ulrik Pedersen‐Bjergaard (ORCID: https://orcid.org/0000-0003-0588-4880)
- Jonah J C Thomas (ORCID: https://orcid.org/0000-0002-9886-0169)
- Julia Katharina Mader (ORCID: https://orcid.org/0000-0001-7854-4233)
- Uffe Søholm (ORCID: https://orcid.org/0000-0003-0848-9421)
- Éric Renard (ORCID: https://orcid.org/0000-0002-3407-7263)
- Rory J. McCrimmon (ORCID: https://orcid.org/0000-0002-3957-1981)
- Simon R. Heller (ORCID: https://orcid.org/0000-0002-2425-9565)
- Mark L. Evans (ORCID: https://orcid.org/0000-0001-8122-8987)
- Bastiaan E. de Galan (ORCID: https://orcid.org/0000-0002-1255-7741)
- Gilberte Martine‐Edith (ORCID: https://orcid.org/0000-0002-4592-3680)
- Vaios Koutroukas (ORCID: https://orcid.org/0000-0001-6120-8057)
- James Shaw (ORCID: https://orcid.org/0000-0002-2893-3211)
- Aikaterina Tziannou (ORCID: https://orcid.org/0009-0009-3445-440X)
- Pratik Choudhary
- Frans Pouwer
Institutions
- University of Copenhagen (DK)
- Centre National de la Recherche Scientifique (FR)
- Steno Diabetes Centers (DK)
- Deakin University (AU)
- University of Leicester (GB)
- Inserm (FR)
- University of Dundee (GB)
- University of Southern Denmark (DK)
- Western Norway University of Applied Sciences (NO)
- King's College London (GB)
- Université de Montpellier (FR)
- Medical University of Graz (AT)
- University of Cambridge (GB)
- Maastricht University Medical Centre (NL)
- Radboud University Medical Center (NL)
- Maastricht University (NL)
- Nordsjællands Hospital (DK)
- Wellcome/MRC Institute of Metabolic Science (GB)
- Cancer Research UK Clinical Trials Unit (GB)
- Institut de Génomique Fonctionnelle (FR)
- Diabetes Victoria (AU)
- University of Birmingham (GB)
- Newcastle University (GB)
- University of Sheffield (GB)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2026-11-03
- DOI
- https://doi.org/10.1111/dom.71504
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00